NCT07203001

A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

An Open-label Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 1 Year – 100 Years
• Healthy volunteers: Not accepted

Summary

The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in pediatric and adult participants with Still's disease

Conditions

• Still´s Disease

Interventions

Type	Name	Description
DRUG	MAS825	Experimental drug

Timeline

• Start date: 2025-11-03
• Primary completion: 2029-05-24
• Completion: 2029-05-24
• First posted: 2025-10-02
• Last updated: 2026-03-30

Locations

22 sites across 8 countries: United States, Canada, France, Germany, Italy, Netherlands, Spain, Turkey (Türkiye)

Regulatory

• FDA-regulated drug study